Search Results
Your search for ,foR matches 32399 pages
Showing 19351 - 19400SNMMI 2017: PET/CT, Clinical Management, and Disease Detection in Prostate Cancer
An estimated one in seven American men will be affected by prostate cancer in their lifetime. Prostate-specific molecular imaging can help to clinically manage the disease much more efficiently, especially if the cancer returns, according to research revealed at the 2017 Annual Meeting of the...
High-Dose First-Line Trastuzumab Maintenance in Metastatic HER2-Positive Gastric Cancer
As reported in the Journal of Clinical Oncology by Shah et al, the phase IIIB HELOISE trial has shown no survival benefit of high-dose vs standard trastuzumab (Herceptin) maintenance plus chemotherapy in the first-line treatment of metastatic gastric or gastroesophageal junction adenocarcinoma....
CancerCare Establishes Patient Values Initiative, Releases Focus Group Assessment
CancerCare has announced the establishment of the CancerCare Patient Values Initiative, a multipronged effort with an aim to reframe the national health-care policy dialogue so that it includes what is important to patients and their families. As the first step of this important project,...
ASTRO Issues Guideline for Use of Stereotactic Radiation in Early-Stage Lung Cancer
The American Society for Radiation Oncology (ASTRO) has issued a new clinical guideline for the use of stereotactic body radiation therapy (SBRT) in early-stage lung cancer. While SBRT is the current standard of care for peripherally located tumors in patients who cannot undergo surgery, the new...
Dutch Study Assesses Long-Term Risk of HPV-Related Carcinoma and Premalignancies After CIN3 Diagnosis
A Dutch study has shown long-lasting risk for human papillomavirus (HPV)-related carcinoma and premalignancies in women with a diagnosis of cervical intraepithelial neoplasia grade 3 (CIN3). The findings were reported by Ebisch et al in the Journal of Clinical Oncology. Study Details The...
Combination of Buparlisib and Fulvestrant in Postmenopausal Women With Advanced Breast Cancer
In the phase III BELLE-2 trial, the addition of the PI3K inhibitor buparlisib to fulvestrant (Faslodex) improved progression-free survival in postmenopausal hormone receptor–positive, HER2-negative advanced breast cancer—but at the cost of excessive toxicity. Results were reported in...
PD-L2 Expression and Clinical Response to Pembrolizumab in Head and Neck Cancer
A study assessing the prevalence and distribution of programmed cell death ligand 2 (PD-L2) in human tumor samples across seven cancer indications, including renal cell carcinoma, bladder, melanoma, non–small cell lung cancer, triple-negative breast cancer, gastric carcinoma, and head and...
Vital Options International Introduces Free eBook, The Cancer Concierge
Between the onslaught of bills and the endless stream of tests and appointments, managing cancer treatment can be overwhelming. There needs to be a good organizing system in place from the very first oncologist appointment. No one understood this better than the Founder of Vital Options ...
AACR Publishes First Set of Screening Recommendations Emerging From Childhood Cancer Predisposition Workshop
The American Association for Cancer Research (AACR) has published its first set of consensus screening recommendations for children with common cancer predisposition syndromes in Clinical Cancer Research. These recommendations emerged from the Childhood Cancer Predisposition Workshop held by the...
Pembrolizumab in Solid Tumors With Mismatch-Repair Deficiency
As reported by Le et al in Science, pembrolizumab (Keytruda) was found to be active across a range of solid tumors with mismatch-repair (MMR) deficiency. Pembrolizumab was recently approved for treatment of patients with unresectable or metastatic microsatellite instability–high (MSI-H) or...
Association of EGFR Copy Number Gain and Outcome With Gefitinib in Advanced Esophageal Cancer
As reported by Petty et al in the Journal of Clinical Oncology, analysis of outcomes in the UK phase III Cancer Esophagus Gefitinib trial showed an overall survival benefit with second-line gefitinib (Iressa) in patients with advanced esophageal cancer who had epidermal growth factor receptor...
Adding Abemaciclib to Fulvestrant in Hormone Receptor–Positive, HER2-Negative Breast Cancer
In the phase III MONARCH 2 trial reported at the recent ASCO Annual Meeting and in the Journal of Clinical Oncology by Sledge et al, the addition of the selective cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor abemaciclib to fulvestrant (Faslodex) improved progression-free survival in hormone...
Oncologist Barbara L. McAneny, MD, FASCO, MACP, Elected AMA President-Elect
Physicians gathered at the Annual Meeting of the American Medical Association (AMA) elected Barbara McAneny, MD, FASCO, MACP, an oncologist from Albuquerque, New Mexico, as the new President-Elect of the physicians' organization. Following a year-long term as President-Elect, Dr. McAneny will...
First Analysis of AACR Project GENIE Data Published
The first analysis of nearly 19,000 de-identified genomic records from the American Association for Cancer Research (AACR) international data-sharing initiative known as AACR Project Genomics Evidence Neoplasia Information Exchange (GENIE) was recently published in Cancer Discovery. In addition to ...
ASCO 2017: SWOG Clinical Trials Have Added More Than 3 Million Years of Life for Patients With Cancer
For an investment of $125 for each year of life gained since the 1950s, the National Cancer Institute (NCI)-funded SWOG clinical trials program has added 3.34 million years of life for patients with cancer in the United States because of successful therapies that were proved through its trials....
Sacituzumab Govitecan in Previously Treated Patients With Metastatic NSCLC
As reported by Heist et al in the Journal of Clinical Oncology, the antibody-drug conjugate sacituzumab govitecan showed activity in patients with previously treated metastatic non–small cell lung cancer (NSCLC). Sacituzumab targets Trop-2, present on many solid tumors; govitecan is the...
Melanoma-Specific Survival With Completion Dissection vs Observation for Sentinel Node Metastasis
The phase III MSLT-II trial showed that completion dissection was not associated with improved melanoma-specific overall survival vs observation in patients with sentinel node metastasis, although a benefit was observed in regional disease control. The findings were reported in The New England...
Memorial Sloan Kettering Cancer Center’s ‘Visible Ink’ Writing Program Gives Voice to the Experiences of Cancer Survivors
On April 3, 2017, Memorial Sloan Kettering Cancer Center (MSKCC) in New York celebrated its ninth year of live performances of the cancer experience written by survivors participating in the center’s Visible Ink writing program. The evening’s performances were the culmination of months-long...
A Remembrance of H. Jean Khoury, MD
Winship Cancer Institute of Emory University (Winship) is mourning the loss of an esteemed colleague: H. Jean Khoury, MD, died on May 22 at the age of 50, after a year spent battling cancer. His many colleagues and friends remember him as an outstanding physician, researcher, and educator and a...
Cancer Has Made Me a Better Person
Eight years ago, I was on top of the world. I had moved to Los Angeles, California, in 2007, from my home in Poços de Caldas, Brazil, to pursue my dream of launching a singing career in the United States, and was finally making progress. I had just completed composing songs for my debut album and...
Refocusing Doctor-Patient Conversations
BOOKMARK Title: What Patients Say, What Doctors HearAuthor: Danielle Ofri, MDPublisher: Beacon PressPublication date: February 2017Price: $24.95, hardcover, 288 pages Despite our scientific and medical advances, the single most important diagnostic tool is the doctor-patient conversation, which is ...
The Serendipitous Road to Drug Development
BOOKMARK Title: The Drug Hunters: The Improbable Quest to Discover New MedicinesAuthors: Donald R. Kirsch, PhD, and Ogi Ogas, PhDPublisher: Arcade PublishingPublication date: January 2017Price: $24.99, hardcover, 328 pages Only about 1 in 100 drug discovery projects initiated by the pharmaceutical ...
Clofarabine-Based Consolidation in Younger Patients With AML
In a French randomized phase II trial reported in the Journal of Clinical Oncology, Thomas et al found that clofarabine-based consolidation may provide improved relapse-free survival vs conventional high-dose cytarabine in postremission treatment in younger patients with acute myeloid leukemia...
Anthracyclines in HER2-Negative Breast Cancer
As reported by Joanne L. Blum, MD, PhD, of Baylor University Medical Center, Texas Oncology, and colleagues in the Journal of Clinical Oncology, the efficacy analysis of the combined adjuvant Anthracyclines in Early Breast Cancer (ABC) Trials showed better invasive disease-free survival with taxane ...
Ipilimumab vs Placebo in Metastatic Chemotherapy-Naive, Castration-Resistant Prostate Cancer Without Visceral Metastases
In the phase III CA184-095trial reported in the Journal of Clinical Oncology, Tomasz M. Beer, MD, FACP, of the Knight Cancer Institute, Oregon Health and Science University, and colleagues found that ipilimumab (Yervoy) did not increase overall survival vs placebo in men with asymptomatic or...
Androgen Blockade and Salvage Radiation Therapy in Prostate Cancer: Cautious Optimism Amid Unanswered Questions
The recent report of results of RTOG 9601 by Shipley et al in The New England Journal of Medicine1—reviewed in this issue of The ASCO Post—strongly supports the variably used practice of adding “androgen blockade” to salvage radiation therapy in men with a rising prostate-specific antigen (PSA)...
Survival Benefit of Adding Antiandrogen Therapy to Radiation in Recurrent Prostate Cancer: Final Results of RTOG 9601
As reported in The New England Journal of Medicine by W.U. Shipley, MD, of Massachusetts General Hospital and Harvard Medical School, and colleagues in the NRG Oncology Radiation Therapy Oncology Group (RTOG), the final analysis of the phase III RTOG 9601 trial shows that the addition of...
Atezolizumab: Another Therapeutic Option for Patients With Previously Treated Non–Small Cell Lung Cancer
The OAK study—recently reported by Rittmeyer and colleagues and reviewed in this issue of The ASCO Post—is the first study to show patients with previously treated non–small cell lung cancer (NSCLC) treated with a humanized antibody (atezolizumab, Tecentriq) directed against the programmed cell...
Atezolizumab Improves Overall Survival vs Docetaxel in Previously Treated Non–Small Cell Lung Cancer
In the phase III OAK trial reported in The Lancet by Achim Rittmeyer, MD, of Lungenfachklinik Immenhausen, Germany, and colleagues, treatment with the anti–programmed cell death ligand 1 (PD-L1) antibody atezolizumab (Tecentriq) improved overall survival vs docetaxel in previously treated non–small ...
Autologous Transplantation for Myeloma: Don’t Change the Winning Team
Over the past 20 years, the Intergroupe Francophone du Myelome (IFM) and Dr. Michel Attal have pioneered the use of autologous hematopoietic cell transplantation (AHCT) for multiple myeloma in a series of randomized studies. Notable studies include comparisons of planned upfront AHCT vs...
Lenalidomide, Bortezomib, and Dexamethasone With or Without Transplantation in Younger Myeloma Patients
In the French phase III IFM 2009 trial reported in The New England Journal of Medicine by Michel Attal, MD, of the Institut Universitaire du Cancer de Toulouse-Oncopole, and colleagues, consolidation treatment with lenalidomide (Revlimid), bortezomib (Velcade), and dexamethasone (RVD) was...
WHO to Begin Pilot Prequalification of Biosimilars for Cancer Treatment
This year, the World Health Organization (WHO) will launch a pilot project for prequalifying biosimilar medicines, a step toward making some of the most expensive treatments for cancer more widely available in low- and middle-income countries. The decision comes after a 2-day meeting in Geneva...
Brian Marr, MD, Joins Division of Ophthalmic Oncology at NewYork-Presbyterian/Columbia University Medical Center
Brian Marr, MD, has joined the Department of Ophthalmology at NewYork-Presbyterian/Columbia University Medical Center as Director of the Division of Ophthalmic Oncology. He will also serve as Professor of Ophthalmology at Columbia University Medical Center. With Dr. Marr’s arrival,...
Brian Wolpin, MD, MPH, Named Director of Gastrointestinal Cancer Center at Dana-Farber
Brian Wolpin, MD, MPH, has been named the new Director of the Gastrointestinal Cancer Center at Dana-Farber Cancer Institute. Dr. Wolpin is Associate Professor of Medicine at Harvard Medical School and was appointed earlier this year as the Robert T. and Judith B. Hale Chair in Pancreatic Cancer...
Combinations of Novel Treatment Approaches Continue to Make Progress in Overcoming Challenges of Pediatric Brain Tumors
Nearly 2,500 children in the United States are diagnosed with brain tumors each year, making these malignancies among the most common solid tumors in children and adolescents. Despite advances over the past few decades, the treatment of brain tumors remains one of the most challenging clinical...
Geriatric Oncology: A Multidisciplinary Approach in a Global Environment
Geriatrics for the Oncologist is guest edited by Stuart M. Lichtman, MD, FACP, FASCO, and developed in collaboration with the International Society of Geriatric Oncology (SIOG). Dr. Lichtman is an Attending Physician at Memorial Sloan Kettering Cancer Center, Commack, New York, and Professor of...
Lisa A. Carey, MD, and Richard S. Finn, MD, on Breast Cancer: Findings From the PALOMA-1/TRIO 18 Trial
Lisa A. Carey, MD, of the University of North Carolina, and Richard S. Finn, MD, of UCLA Medical Center, discuss phase II overall survival findings on palbociclib in combination with letrozole vs letrozole alone for front-line treatment of ER+/HER2– advanced breast cancer. (Abstract 1001)
ASCO Launches Volunteer Corps
ASCO is very fortunate to have an active member base eager to volunteer, share expertise, and give back to the oncology community. Currently, more than 2,000 volunteers are engaged on ASCO committees, subcommittees, working groups, panels, task forces, editorial boards, and in various training...
ASCO COME HOME Offers Direct Support to Practices Transitioning to Quality Payment Program
ASCO is making it easier for practices to understand and prepare for the transition to the Quality Payment Program (QPP) in the years ahead with its ASCO COME HOME initiative. ASCO COME HOME provides readiness assessment tools to help practices evaluate whether or not they are ready to transition...
Proposed Categories of Cancer Survivors Aim to Bring Survivorship Into Precision Medicine Era
Care for people who have survived or are living with cancer should acknowledge the heterogeneity of their needs and experiences and should reflect the same level of personalization that is now guiding active cancer therapy. At a time when more people are surviving cancer than ever before, new...
Help Your Patients Catch Up on the Latest Research From the 2017 ASCO Annual Meeting
On the Cancer.Net blog (www.cancer.net/blog), your patients can learn about the research highlighted at the 2017 ASCO Annual Meeting, including what it means for their care and treatment. They can also follow the blog for additional updates from the Meeting, including podcasts with ASCO experts...
ASCO Resources Help Practices Navigate Quality Reporting Under MACRA
The Quality Payment Program (QPP), established by the Medicare Access and CHIP Reauthorization Act (MACRA), launched this January and is being implemented in oncology practices across the country. In 2017, practices must report some quality data in order to avoid financial penalties in 2019. ASCO...
Leave a Legacy of Hope
By including a planned gift to the Conquer Cancer Foundation in your estate plans, you can help make a dramatic difference for cancer patients years—even decades—into the future. With just one small change to your will or trust, your planned gift of any size will deliver a big impact, and: Your...
Wendy S. Rubinstein, MD, PhD, FACMG, FACP, Joins CancerLinQ LLC as Division Director, Clinical Data Management and Curation
CancerLinQ LLC, a wholly owned nonprofit subsidiary of ASCO, has -announced that Wendy S. Rubinstein, MD, PhD, FACMG, FACP, will be its first Division Director, Clinical Data Management and Curation. Dr. Rubinstein will oversee the team working to securely process and analyze the -CancerLinQ®...
Combination Therapy With Pembrolizumab in Metastatic Nonsquamous NSCLC
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On May 10, 2017, pembrolizumab (Keytruda) was granted accelerated...
FDA Broadens Ceritinib Indication
On May 26, 2017, the U.S. Food and Drug Administration (FDA) granted regular approval to ceritinib (Zykadia), a kinase inhibitor for patients with metastatic non–small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. In April...
Selected Novel Agents in Development for Multiple Myeloma
Here are several abstracts selected from the proceedings of the 2016 America Society of Hematology (ASH) Annual Meeting & Exposition, highlighting newer therapeutics for the development for patients with relapsed or refractory multiple myeloma. For full details of these study abstracts, visit...
Targeting the Androgen Receptor in Breast Cancer
One of the most active areas of research in breast cancer involves the targeting of the androgen receptor. Trials underway for androgen receptor antagonists and modulators, alone and in various combinations of available agents and novel therapies, are yielding encouraging early results. At the 2017 ...
Expert Point of View: Michael Berry, MD
Michael Berry, MD, a breast surgeon who is Director of the Margaret West Comprehensive Breast Center at The West Cancer Center, Memphis, told the The ASCO Post that these findings “echo what surgeons already know,” which is that lymphedema is a result of multiple insults to the axilla. But one...
Lymphedema Risk: It’s Not Just About the Surgery
In a study from the Mayo Clinic, Rochester, Minnesota, the risk of lymphedema in a population-based breast cancer cohort was related to multimodality therapy and not axillary surgery alone, investigators reported at the American Society of Breast Surgeons (ASBrS) Annual Meeting.1 “Most patients...
